JP2007532665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532665A5 JP2007532665A5 JP2007508496A JP2007508496A JP2007532665A5 JP 2007532665 A5 JP2007532665 A5 JP 2007532665A5 JP 2007508496 A JP2007508496 A JP 2007508496A JP 2007508496 A JP2007508496 A JP 2007508496A JP 2007532665 A5 JP2007532665 A5 JP 2007532665A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- formula
- hiv integrase
- compound
- integrase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 262
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 165
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 165
- 125000000623 heterocyclic group Chemical group 0.000 claims 34
- 125000003107 substituted aryl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 23
- 125000000547 substituted alkyl group Chemical group 0.000 claims 22
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 19
- -1 polyethyleneoxy Polymers 0.000 claims 19
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 17
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 125000006239 protecting group Chemical group 0.000 claims 15
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 13
- 229910019142 PO4 Inorganic materials 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 150000003951 lactams Chemical class 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 12
- 239000010452 phosphate Substances 0.000 claims 12
- 229940124530 sulfonamide Drugs 0.000 claims 12
- 150000003456 sulfonamides Chemical class 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 10
- 150000001408 amides Chemical class 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 9
- 150000002596 lactones Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 8
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000004419 alkynylene group Chemical group 0.000 claims 8
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims 8
- 125000005110 aryl thio group Chemical group 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 150000002825 nitriles Chemical class 0.000 claims 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000005208 trialkylammonium group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 150000001540 azides Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 4
- 150000001350 alkyl halides Chemical class 0.000 claims 4
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000007942 carboxylates Chemical class 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 210000000265 leukocyte Anatomy 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108010002459 HIV Integrase Proteins 0.000 claims 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 150000001356 alkyl thiols Chemical class 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- GZGZMAJKCUAIRS-UHFFFAOYSA-N piperazin-1-yl sulfamate Chemical compound NS(=O)(=O)ON1CCNCC1 GZGZMAJKCUAIRS-UHFFFAOYSA-N 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- HFHDGHOGHWXXDT-ZSOIEALJSA-N (z)-1-[5-[(4-fluorophenyl)methyl]furan-2-yl]-3-hydroxy-3-(1h-1,2,4-triazol-5-yl)prop-2-en-1-one Chemical compound N=1C=NNC=1C(/O)=C/C(=O)C(O1)=CC=C1CC1=CC=C(F)C=C1 HFHDGHOGHWXXDT-ZSOIEALJSA-N 0.000 claims 1
- QGCIARGIIYMTGU-PTNGSMBKSA-N (z)-4-(3-benzylphenyl)-4-hydroxy-2-oxobut-3-enoic acid Chemical compound OC(=O)C(=O)\C=C(/O)C1=CC=CC(CC=2C=CC=CC=2)=C1 QGCIARGIIYMTGU-PTNGSMBKSA-N 0.000 claims 1
- RLOQBKJCOAXOLR-UHFFFAOYSA-N 1h-pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC=CN1 RLOQBKJCOAXOLR-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000006323 alkenyl amino group Chemical group 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000006319 alkynyl amino group Chemical group 0.000 claims 1
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical class O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- 0 C[C@](CCC1(C(C)(C)O)OC1)[C@@]1[C@]([C@]([C@@](C2=C3CCC(C(C)(C)[C@]4*)[C@]2(C)C[C@]4O*)O)O)(C(C)=O)C3=CC1 Chemical compound C[C@](CCC1(C(C)(C)O)OC1)[C@@]1[C@]([C@]([C@@](C2=C3CCC(C(C)(C)[C@]4*)[C@]2(C)C[C@]4O*)O)O)(C(C)=O)C3=CC1 0.000 description 26
- CDRSBPYJKRZQAY-UHFFFAOYSA-N COC(N1CCOCC1)=O Chemical compound COC(N1CCOCC1)=O CDRSBPYJKRZQAY-UHFFFAOYSA-N 0.000 description 1
- BVCPOBBMOIJWQM-UHFFFAOYSA-N COS(N1CCOCC1)(=O)=O Chemical compound COS(N1CCOCC1)(=O)=O BVCPOBBMOIJWQM-UHFFFAOYSA-N 0.000 description 1
- WXSIWFBRRFAVJQ-UHFFFAOYSA-N O=C(CC1CC1)N1CCOCC1 Chemical compound O=C(CC1CC1)N1CCOCC1 WXSIWFBRRFAVJQ-UHFFFAOYSA-N 0.000 description 1
- PVBOVFLECGDSBT-UHFFFAOYSA-N O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cc(cc1)I)c1C(NNC(c(cccc1)c1S)=O)=O)=O Chemical compound O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cc(cc1)I)c1C(NNC(c(cccc1)c1S)=O)=O)=O PVBOVFLECGDSBT-UHFFFAOYSA-N 0.000 description 1
- UXDSBDGMFUNUCO-UHFFFAOYSA-N O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cccc1)c1C(NNC(c(c([AlH2])ccc1)c1S)=O)=O)=O Chemical compound O=C(c(cccc1)c1S)NNC(c1ccccc1SSc(cccc1)c1C(NNC(c(c([AlH2])ccc1)c1S)=O)=O)=O UXDSBDGMFUNUCO-UHFFFAOYSA-N 0.000 description 1
- ATIQTVUVGCQYEV-UHFFFAOYSA-N O=C(c(cccc1)c1SSc(cccc1)c1C(NNC(c(ccc(I)c1)c1SSc1c2cccc1)=O)=O)NNC2=O Chemical compound O=C(c(cccc1)c1SSc(cccc1)c1C(NNC(c(ccc(I)c1)c1SSc1c2cccc1)=O)=O)NNC2=O ATIQTVUVGCQYEV-UHFFFAOYSA-N 0.000 description 1
- QHZMUUXGGURBEN-UHFFFAOYSA-M OC(C1OC(c(cc2O)cc(O[AlH2])c2O)=O)C(O)OC1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O Chemical compound OC(C1OC(c(cc2O)cc(O[AlH2])c2O)=O)C(O)OC1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O QHZMUUXGGURBEN-UHFFFAOYSA-M 0.000 description 1
- BHSGUMGKESMLOG-UHFFFAOYSA-N OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC(C(c2c(cc3O)O)=O)=C(C(CC4O)=CC=C4O)Oc2c3[AlH2])OC1O Chemical compound OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC(C(c2c(cc3O)O)=O)=C(C(CC4O)=CC=C4O)Oc2c3[AlH2])OC1O BHSGUMGKESMLOG-UHFFFAOYSA-N 0.000 description 1
- ARMGDESJBVCPBB-UHFFFAOYSA-N OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC2=C(c(cc3)cc(O)c3O)Oc3cc(O)cc(O)c3C2=O)OC1O Chemical compound OC(c(cc1O)cc(O)c1O)OC(C1O)C(OC2=C(c(cc3)cc(O)c3O)Oc3cc(O)cc(O)c3C2=O)OC1O ARMGDESJBVCPBB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56267804P | 2004-04-14 | 2004-04-14 | |
| PCT/US2005/012520 WO2005117904A2 (en) | 2004-04-14 | 2005-04-11 | Phosphonate analogs of hiv integrase inhibitor compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532665A JP2007532665A (ja) | 2007-11-15 |
| JP2007532665A5 true JP2007532665A5 (https=) | 2008-06-19 |
Family
ID=35276373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508496A Pending JP2007532665A (ja) | 2004-04-14 | 2005-04-11 | Ｈｉｖインテグラーゼ阻害剤化合物のホスホネート類似物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20080076738A1 (https=) |
| EP (1) | EP1742642B1 (https=) |
| JP (1) | JP2007532665A (https=) |
| AT (1) | ATE411030T1 (https=) |
| AU (1) | AU2005249363A1 (https=) |
| CA (1) | CA2562713A1 (https=) |
| DE (1) | DE602005010413D1 (https=) |
| DK (1) | DK1742642T3 (https=) |
| ES (1) | ES2315922T3 (https=) |
| PL (1) | PL1742642T3 (https=) |
| PT (1) | PT1742642E (https=) |
| SI (1) | SI1742642T1 (https=) |
| WO (1) | WO2005117904A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035577A2 (en) * | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| AR057023A1 (es) * | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
| WO2006122403A1 (en) | 2005-05-19 | 2006-11-23 | Merck Frosst Canada Ltd. | Quinoline derivatives as ep4 antagonists |
| EP1906971A2 (en) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| CA2642321A1 (en) * | 2006-02-20 | 2007-08-30 | Alembic Limited | An improved process for the preparation of biphosphonic derivatives |
| AU2007254190A1 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Integrase inhibitors |
| WO2009026206A1 (en) * | 2007-08-21 | 2009-02-26 | University Of Toledo | Method for synthesizing xanthohumol |
| US20090291921A1 (en) * | 2007-11-20 | 2009-11-26 | Gilead Sciences, Inc. | Integrase inhibitors |
| WO2010011814A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2448766T3 (es) * | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Profármacos de dolutegravir |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| KR101733625B1 (ko) | 2008-12-11 | 2017-05-10 | 시오노기세야쿠 가부시키가이샤 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| LT3494972T (lt) * | 2010-01-27 | 2024-03-12 | Viiv Healthcare Company | Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| US20120142701A1 (en) * | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| GB2497476B (en) | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| KR101365849B1 (ko) * | 2012-03-28 | 2014-02-24 | 경동제약 주식회사 | 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| WO2019113523A1 (en) | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
| CN111484529A (zh) * | 2019-01-28 | 2020-08-04 | 奥锐特药业股份有限公司 | 一种合成替诺福韦单苯酯的方法 |
| CN112946154B (zh) * | 2021-02-05 | 2022-10-25 | 石家庄四药有限公司 | 他汀类药物起始物料及其对映异构体的hplc检测方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH385846A (de) * | 1960-03-31 | 1964-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz |
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5883255A (en) * | 1990-10-31 | 1999-03-16 | Smithkline Beecham Corporation | Substituted indolizino 1,2-b!quinolinones |
| ES2104862T3 (es) * | 1991-02-07 | 1997-10-16 | Roussel Uclaf | Derivados biciclicos nitrogenados, su procedimiento de preparacion, sus productos intermedios obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. |
| EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
| US5639881A (en) * | 1991-11-08 | 1997-06-17 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives |
| TW304945B (https=) * | 1992-06-27 | 1997-05-11 | Hoechst Ag | |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| DK0736020T3 (da) * | 1993-12-17 | 2000-08-07 | Procter & Gamble | 6-(2-imidazolinylamino)quinolinforbindelser, der er egnede som alfa-2-adrenoceptoragonister |
| US5538988A (en) * | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| DE19613591A1 (de) * | 1996-04-04 | 1997-10-09 | Hoechst Ag | Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5854275A (en) * | 1996-05-16 | 1998-12-29 | Pfizer Inc. | Cyclic imide derivatives |
| US6310211B1 (en) * | 1996-09-10 | 2001-10-30 | Pharmacia & Upjohn Company | 8-hydroxy-7-substituted quinolines as anti-viral agents |
| DE19738005A1 (de) * | 1997-08-30 | 1999-03-04 | Bayer Ag | Verwendung von substituierten 1,1-Bisphosphonaten |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| EP1086102A1 (en) * | 1998-06-10 | 2001-03-28 | Arena Pharmaceuticals, Inc. | Acetylcholine enhancers |
| WO2000000475A1 (en) * | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
| US6187907B1 (en) * | 1998-08-31 | 2001-02-13 | James Chen | Triple helix coil template having a biologically active ligand |
| AU3118200A (en) * | 1998-12-14 | 2000-07-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US6245806B1 (en) * | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
| AU8009900A (en) * | 1999-10-13 | 2001-04-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
| PE20011349A1 (es) * | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6525049B2 (en) * | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
| AR036256A1 (es) * | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| WO2003091264A2 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| WO2004035577A2 (en) * | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
-
2005
- 2005-04-11 WO PCT/US2005/012520 patent/WO2005117904A2/en not_active Ceased
- 2005-04-11 AU AU2005249363A patent/AU2005249363A1/en not_active Abandoned
- 2005-04-11 DE DE602005010413T patent/DE602005010413D1/de not_active Expired - Fee Related
- 2005-04-11 DK DK05804767T patent/DK1742642T3/da active
- 2005-04-11 AT AT05804767T patent/ATE411030T1/de not_active IP Right Cessation
- 2005-04-11 SI SI200530545T patent/SI1742642T1/sl unknown
- 2005-04-11 JP JP2007508496A patent/JP2007532665A/ja active Pending
- 2005-04-11 EP EP05804767A patent/EP1742642B1/en not_active Expired - Lifetime
- 2005-04-11 US US11/578,649 patent/US20080076738A1/en not_active Abandoned
- 2005-04-11 PL PL05804767T patent/PL1742642T3/pl unknown
- 2005-04-11 CA CA002562713A patent/CA2562713A1/en not_active Abandoned
- 2005-04-11 PT PT05804767T patent/PT1742642E/pt unknown
- 2005-04-11 ES ES05804767T patent/ES2315922T3/es not_active Expired - Lifetime
- 2005-04-14 US US11/106,363 patent/US20060116356A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532665A5 (https=) | ||
| TWI243176B (en) | Chemical compounds comprising nucleoside phosphoramidates, their preparation and their therapeutic uses, and pharmaceutical compositions comprising the compounds | |
| AU2003231765B2 (en) | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such | |
| ES2489645T3 (es) | Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión | |
| JP3121343B2 (ja) | ポリ―４―アミノ―２―カルボキシ―１―メチル化合物の新規ウレイド誘導体 | |
| AU2020323429A1 (en) | Urea compound for antagonizing LPA1 receptor | |
| JPH0623193B2 (ja) | 新規なジスタマイシンａ同族体、その製造方法およびそれを含有する医薬組成物 | |
| JP2006501202A5 (https=) | ||
| JP4312264B2 (ja) | アクリロイル置換ジスタマイシン誘導体、その製造法、および抗腫瘍および抗ウイルス剤としてのその使用 | |
| KR20010103782A (ko) | 항염증성, 진통성 및 항혈전 활성을 갖는 니트록시 유도체 | |
| JP2015502974A (ja) | 抗微生物療法のための三環式ホウ素化合物 | |
| HU213507B (en) | Process for producing substituted acryloyl-pyrrole derivatives and pharmaceutical compositions comprising same | |
| CA2271299A1 (en) | Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| FR2585019A1 (fr) | Derives de distamycine et leur procede de fabrication | |
| JPH08508720A (ja) | ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物 | |
| DE69705622T2 (de) | Distamycin derivate, verfahren zu ihrer herstellung sowie ihre verwendung als antitumor und antiviral wirkstoffe | |
| JP2007517900A5 (https=) | ||
| EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
| PL150841B1 (en) | Purine compounds. | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| US5663161A (en) | Anti-viral triaza compounds | |
| DE69908371T2 (de) | Thioethergruppen enthaltende distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
| JPH02160769A (ja) | 新規な２′―ハロメチリデン、２′―エテニリデン及び２′―エチニルアデノシン誘導体類 | |
| US20070191373A1 (en) | Heterocyclic compounds for use in the treatment of viral infections | |
| TWI439463B (zh) | 青蒿素之二聚衍生物及其在抗癌治療之應用 |